ORP-105 is a non-addictive, centrally-acting, non-opiate acetaminophen analog for the management of pain. In preclinical and in vitro proof of concept studies, ORP-105 reduced pain-associated behaviors in both nociceptive and inflammatory phases at a rate similar to morphine, with no evidence of hepatotoxicity as its unique design avoids the formation of metabolites that cause liver injury.